Soleno Therapeutics Inc (NASDAQ:SLNO) Director Edgar Engleman bought 1,085,480 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was purchased at an average price of $1.84 per share, with a total value of $1,997,283.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Soleno Therapeutics Inc (NASDAQ:SLNO) traded up $0.01 during trading on Thursday, hitting $1.83. 10,900 shares of the company were exchanged, compared to its average volume of 46,786. The firm has a market capitalization of $18.30, a price-to-earnings ratio of -1.14 and a beta of 6.00. Soleno Therapeutics Inc has a fifty-two week low of $1.32 and a fifty-two week high of $4.55.
A number of research analysts have recently issued reports on SLNO shares. Maxim Group set a $25.00 target price on shares of Soleno Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 12th. ValuEngine upgraded shares of Soleno Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, October 6th. Finally, cut their target price on shares of Soleno Therapeutics from $25.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th.
Soleno Therapeutics Company Profile
Soleno Therapeutics, Inc, formerly Capnia, Inc, is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief.
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.